A Mayo Clinic Trial Tested a Purified Exosome Product on Wounds: Safe, but No Faster Healing

In 2026, a research team at the Mayo Clinic in Minnesota published the first human trial of a purified exosome product intended to help skin wounds heal. Exosomes are tiny, cell-derived particles that carry proteins, lipids and genetic signals between cells, and there has been growing interest in whether concentrated, purified exosomes from stem cells could be used as a therapy to speed up tissue repair. This trial set out to answer the most basic question first: is it safe to use in people at all.

The study was carried out in seven patients who each had two matched surgical wounds from a skin graft procedure. One wound on each patient was treated with the exosome product, the other received standard wound care, allowing each patient to act as their own control. The wounds treated with the exosome product reached full healing, meaning complete re-epithelialisation, at a median of 18.5 days. The wounds treated with standard care reached full healing at a median of 19.25 days. That difference is small, and the study did not find it to be statistically significant, meaning it is consistent with no real difference between the two treatments.

So the honest, one-line summary of this trial is that the exosome product was safe, with no treatment-related adverse events reported in any of the seven patients, but it did not heal wounds meaningfully faster than the standard care patients were already receiving. That is a useful and genuinely important result, just not the kind of result that tends to make it into marketing material.

It is worth being upfront about the size and design of this study. Seven patients is small by the standards of a definitive efficacy trial, and this was explicitly a phase 1b trial, the stage of clinical research primarily focused on confirming a new treatment is safe in humans and working out an appropriate dose, rather than proving it works. Phase 1b trials are not designed or statistically powered to detect anything but a fairly large effect, so a lack of statistically significant benefit at this stage does not rule out a smaller benefit that a larger trial might detect, nor does it confirm one exists.

What makes this trial worth covering is not its size but its design. Using a split design, where each patient receives both the experimental treatment and the standard comparator on matched wounds, is one of the more rigorous ways to run a small early trial, because it controls for differences between patients that could otherwise muddy the results. The researchers also measured healing using two validated, structured scoring tools, the Vancouver Scar Scale and a photographic wound assessment tool, rather than relying on subjective impressions.

So while this is early-stage research, it is a properly randomised, controlled, if small, human trial, and the honest result is that on the primary question people actually care about, does it heal wounds faster, the answer so far is no. That is a genuinely useful data point, and one that a lot of exosome marketing simply does not mention.

Patients in the trial had at least two equal-sized split-thickness skin graft donor site wounds, the area of skin from which a graft is taken, which tends to be a well-understood and fairly standardised wound type for this kind of comparison. Participants were split into a low-dose and a high-dose group for the exosome product, allowing the researchers to also get an early read on whether a higher concentration behaved any differently in terms of both safety and healing time.

Safety was assessed through the occurrence of adverse events, laboratory blood tests, vital signs and physical examination, the standard toolkit for an early-phase safety trial. Wound healing itself was scored using the Vancouver Scar Scale, which rates factors like pigmentation, pliability, height and vascularity of the healing tissue, alongside a photographic wound assessment tool that tracks the wound's appearance over time using standardised photography.

The mean age of participants was 49.3 years, and the study reported no adverse events attributable to the treatment in either the low-dose or high-dose groups, including no concerning changes in blood tests, vital signs or physical examination findings. Given the small sample, this is a meaningful early signal on safety even though it cannot rule out rarer side effects that a study of only seven people is simply too small to detect.

One of the researchers on this study, and the most senior author on the paper, is the chief executive officer of RION, Inc., the company that manufactures the purified exosome product being tested. Another author on the paper serves as a paid consultant to the same company. Both relationships are disclosed transparently in the published paper's conflict of interest statement, which is exactly the kind of disclosure that should be there and that is not always present in exosome research more broadly.

This does not mean the trial's results are unreliable, and a disclosed conflict of interest is a very different situation from an undisclosed one. The methodology, the split-wound design, the use of standardised scoring tools and the honest reporting of a non-significant result, including in the paper's own conclusion that future larger trials are needed to validate efficacy, all point to a study conducted and reported with appropriate rigour despite the financial relationship involved.

Still, it is worth knowing that the people developing and commercialising this specific product were also involved in designing and running the trial that tested it, which is a common pattern in early-stage medical device and biologic research, and one readers should keep in mind when weighing how a company then chooses to describe or market results like these.

It is important to be precise about what this trial does and does not tell us about exosome therapy as it is actually offered in Ireland. The product in this trial is an injected, purified exosome preparation, developed as an investigational product specifically for wound care, and tested on surgical skin graft donor sites in a hospital setting. Irish clinics currently offering exosome therapy do so almost entirely for aesthetic purposes, applying a topical exosome solution to the face or scalp after microneedling to improve skin texture or support hair restoration, generally using products sourced from stem cell-derived or plant-derived origins rather than the specific investigational product tested here.

Different product, different route of delivery, different clinical purpose and a different patient population all mean this trial's result cannot simply be read across to say anything definitive about whether the topical aesthetic exosome treatments sold in Irish clinics work or do not work. Those products have not been tested in a trial of this design, and the evidence for topical, aesthetic exosome use currently rests mainly on smaller pilot studies and split-face designs rather than this kind of randomised safety trial.

What this trial does usefully illustrate is the current state of exosome science more broadly: even a well-designed, properly randomised trial of a purified, pharmaceutical-grade exosome product, backed by a company with a direct commercial interest in a positive result, did not find a clear efficacy signal in its first human test. That is a reasonable note of caution to carry into how confidently any exosome product, aesthetic or otherwise, should be marketed at this stage.

Exosome-based products occupy a genuinely unsettled regulatory position. The Health Products Regulatory Authority has published general guidance for patients considering newer cell-based and cell-derived therapies, noting that providers of these treatments are not permitted to promote them to the public for unapproved uses, that some such treatments may not be properly tested and could carry risk, and that patients should be wary of dramatic claims, direct-to-consumer advertising and vague answers about where a treatment is manufactured or how it is regulated.

In Ireland, exosome therapy is offered by aesthetic and dermatology clinics, mostly concentrated in Dublin, generally as a topical treatment combined with microneedling for facial skin quality or hair restoration, at a typical cost of EUR 300 to EUR 600 per session (prices last checked in September 2026), with a course of three to six sessions commonly recommended. This is a materially different clinical context from a hospital-based, injected, investigational wound-care product being tested in a formal clinical trial pathway.

Anyone considering an exosome treatment in Ireland, for any purpose, should ask the clinic directly where the product is sourced, what regulatory status it has, and what specific evidence supports its particular formulation and delivery method, rather than assuming that positive-sounding exosome research generally, including studies like the one covered here, applies to the specific product being offered to them.

It would be easy to read a headline like exosome trial finds no benefit and conclude the whole field is a dead end, but that misreads what this particular result shows. A phase 1b safety trial in seven patients establishing that a product does not have an obvious, large effect on wound healing speed is a normal, expected early step in medical research, not a verdict on exosome science as a whole. Many treatments that eventually prove useful for one condition show no clear benefit in their first, smallest human trials, and many that never pan out look promising early on before larger trials correct the picture.

What matters is that this is exactly the kind of honest reporting that should happen more often in a field with as much commercial enthusiasm around it as regenerative and exosome medicine currently has. The authors did not overstate their findings, disclosed their financial relationship to the product's manufacturer, and explicitly called for larger trials before drawing conclusions about efficacy. That is the standard every exosome study, and every treatment on this site, should be held to.

For anyone in Ireland considering an exosome treatment today, the practical takeaway is not that exosomes definitely do not work, but that the evidence for any specific exosome product and application is generally much earlier and thinner than marketing materials tend to suggest, and that safety data from one product for one purpose should not be assumed to apply to a different product being sold for a different purpose.

The Mayo Clinic team was explicit that this trial's purpose was to establish safety and gather preliminary data, and that larger trials, properly powered to detect efficacy, will be needed before any claim about whether this specific exosome product actually improves wound healing can be made with confidence. That is the natural next step for this particular product, and it is a step that has not yet happened.

More broadly, exosome research across dermatology, wound care and orthopaedics is still at a relatively early stage compared with fields like PRP, where multiple large meta-analyses of randomised trials now exist. Most published exosome studies to date, including in aesthetic applications such as facial rejuvenation and post-surgical scar management, remain small pilot studies, split-face or split-scar designs, or early-phase safety trials rather than the larger, definitively powered efficacy trials the field will eventually need.

Gerovia will continue tracking this research area and will cover larger trials as they are published, including studies that find genuine benefit and studies, like this one, that do not. A null or inconclusive result from a rigorous trial is not a failure of the research, and reporting it honestly is more useful to readers considering these treatments than only reporting the studies that happen to find a positive effect.